BrightGene advances obesity drug toward Chinese approval, eyes Western data and partners
read at Endpoints ↗RegulatoryPositive
BrightGene has submitted its obesity GLP-1 candidate to Chinese regulators after reporting strong Phase 3 results.
The company says data from Western trials are expected to be even more robust, which could support a broader market launch.
BrightGene is also seeking a commercial partner to handle sales outside China, indicating a strategy to expand globally.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BrightGene looks to the West as obesity shot nears China approval”
read at Endpoints ↗91 words · retrieved Jul 2
comments(0)
5-min edit window · permanent after that